ivermectin effective in outpatients with mild to moderate COVID-19
Ivermectin effective in treating outpatients with mild to moderate COVID-19 suggests a recent study published in the JAMA.
The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. A study was conducted to evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with placebo for the treatment of early mild to moderate COVID-19.
ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30 years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022, with follow-up data through May 31, 2022, at 93 sites in the US.
Participants were randomized to receive ivermectin, 400 μg/kg (n = 817), daily for 3 days or placebo (n = 774). Time to sustained recovery, defined as at least 3 consecutive days without symptoms were main outcomes. There were 7 secondary outcomes, including a composite of hospitalization or death by day 28.
Results:
- Among 1800 participants who were randomized 1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07
- The median time to recovery was 12 days in the ivermectin group and 13 days in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group
- The most common serious adverse events were COVID-19 pneumonia and venous thromboembolism
Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19.
Reference:
Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. Published online October 21, 2022. doi:10.1001/jama.2022.18590
Keywords:
Naggie S, Boulware DR, Lindsell CJ, Effect, Ivermectin, Placebo, Time, Sustained, Recovery, Outpatients, Mild, Moderate, COVID-19, Randomized, Clinical Trial, JAMA
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.